

## Literatur

- O'Sullivan BP, Freedman SD. Cystic fibrosis. *The Lancet*. 2009 May 30;373(9678):1891–904.
- Dijk FN, McKay K, Barzi F, Gaskin KJ, Fitzgerald DA. Improved survival in cystic fibrosis patients diagnosed by newborn screening compared to a historical cohort from the same centre. *Arch Dis Child* [Internet]. 2011 Dec [cited 2023 Nov 21];96(12):1118–23. Available from: <https://pubmed.ncbi.nlm.nih.gov/21994242/>
- Schütz K, Kotsendorn J, Janzen N, Fuge J, Grewendorf S, Klemann C, et al. The First 4 Years - Outcome of Children Identified by Newborn Screening for CF in Germany. *Klin Padiatr* [Internet]. 2022 Sep 21 [cited 2023 Nov 21];234(5):284–92. Available from: <https://pubmed.ncbi.nlm.nih.gov/35098497/>
- Stahl M, Wielpütz MO, Ricklefs I, Dopfer C, Barth S, Schlegtendal A, et al. Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRE-SIS). A Randomized, Double-Blind, Controlled Study. *Am J Respir Crit Care Med* [Internet]. 2019 May 15 [cited 2023 Nov 21];199(10):1238–48. Available from: <https://pubmed.ncbi.nlm.nih.gov/30409023/>
- Stahl M, Steinke E, Graeber SY, Joachim C, Seitz C, Kauczor HU, et al. Magnetic Resonance Imaging Detects Progression of Lung Disease and Impact of Newborn Screening in Preschool Children with Cystic Fibrosis. *Am J Respir Crit Care Med* [Internet]. 2021 Oct 15 [cited 2023 Nov 21];204(8):943–53. Available from: <https://pubmed.ncbi.nlm.nih.gov/34283704/>
- AWMF Leitlinienregister [Internet]. [cited 2023 Nov 21]. Available from: <https://register.awmf.org/de/leitlinien/detail/026-024>
- Filipow N, Stanojevic S, Raywood E, Shannon H, Tanriver G, Kapoor K, et al. Real-world effectiveness of airway clearance techniques in children with cystic fibrosis. *European Respiratory Journal* [Internet]. 2023 Sep 1 [cited 2023 Nov 21];62(3). Available from: <https://erj.ersjournals.com/content/62/3/2300522>
- Gambazza S, Ambrogi F, Carta F, Moroni L, Russo M, Brivio A, et al. Lung clearance index to characterize clinical phenotypes of children and adolescents with cystic fibrosis. *BMC Pulm Med* [Internet]. 2022 Dec 1 [cited 2023 Dec 29];22(1):1–8. Available from: <https://bmcpulmed.biomedcentral.com/articles/10.1186/s12890-022-01903-5>
- Conrad DJ, Billings J, Teneback C, Koff J, Rosenbluth D, Bailey BA, et al. Multi-dimensional clinical phenotyping of a national cohort of adult cystic fibrosis patients. *J Cyst Fibros* [Internet]. 2021 Jan 1 [cited 2023 Nov 21];20(1):91–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/32948498/>
- Pust MM, Wiehlmann L, Davenport C, Rudolf I, Dittrich AM, Tümmler B. The human respiratory tract microbial community structures in healthy and cystic fibrosis infants. *NPJ Biofilms Microbiomes* [Internet]. 2020 Dec 1 [cited 2023 Nov 21];6(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/33319812/>
- Nährlich L, Burkhart M, Wosniok J. Deutsches Mukoviszidose-Register. [cited 2024 Jan 8]; Available from: [www.muko.info](http://www.muko.info)
- Mehraj J, Witte W, Akmatov MK, Layer F, Werner G, Krause G. Epidemiology of *Staphylococcus aureus* nasal carriage patterns in the community. *Curr Top Microbiol Immunol* [Internet]. 2016 Dec 1 [cited 2023 Nov 21];398:55–87. Available from: [https://link.springer.com/chapter/10.1007/82\\_2016\\_497](https://link.springer.com/chapter/10.1007/82_2016_497)
- Dagan A, Cohen-Cymberek M, Shteinberg M, Levine H, Vilozni D, Bezalel Y, et al. Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience. *Respir Med* [Internet]. 2017 Oct 1 [cited 2023 Nov 21];131:225–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/28947035/>
- Lopez A, Daly C, Vega-Hernandez G, MacGregor G, Rubin JL. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. *J Cyst Fibros* [Internet]. 2023 Jul 1 [cited 2023 Nov 21];22(4):607–14. Available from: <https://pubmed.ncbi.nlm.nih.gov/36849331/>
- Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. *N Engl J Med* [Internet]. 2019 Nov 7 [cited 2023 Nov 21];381(19):1809–19. Available from: <https://pubmed.ncbi.nlm.nih.gov/31697873/>
- Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. *Lancet* [Internet]. 2019 Nov 23 [cited 2024 Jan 8];394(10212):1940–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/31679946/>
- Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, et al. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. *N Engl J Med* [Internet]. 2021 Aug 26 [cited 2023 Dec 29];385(9):815–25. Available from: <https://pubmed.ncbi.nlm.nih.gov/34437784/>
- Ramsey B, Correll CU, DeMaso DR, McKone E, Tullis E, Taylor-Cousar JL, et al. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events. *Am J Respir Crit Care Med* [Internet]. 2023 Oct 27 [cited 2023 Nov 21]; Available from: <https://pubmed.ncbi.nlm.nih.gov/37890129/>
- HIGHLIGHTS OF PRESCRIBING INFORMATION. 2021 [cited 2023 Nov 21]; Available from: [www.fda.gov/medwatch](http://www.fda.gov/medwatch).
- GBA. Zusammenfassende Dokumentation über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII-Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V Ivacaftor. 2021;
- Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, et al. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. *Lancet Respir Med* [Internet]. 2023 Apr 1 [cited 2023 Nov 21];11(4):329–40. Available from: <http://www.thelancet.com/article/S2213260022004349/fulltext>
- Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, et al. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. *Am J Respir Crit Care Med* [Internet]. 2022 Mar 1 [cited 2023 Nov 21];205(5):529–39. Available from: <https://pubmed.ncbi.nlm.nih.gov/34784492/>
- Dittrich AM, Sieber S, Naehrlich L, Burkhart M, Hafkemeyer S, Tümmler B. Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of *Staphylococcus aureus* and *Pseudomonas aeruginosa* dependent on age and lung function in people with cystic fibrosis. *Int J Infect Dis* [Internet]. 2023 Feb [cited 2023 Dec 29];139:124–31. Available from: <https://pubmed.ncbi.nlm.nih.gov/38032621/>
- Sui H, Xu X, Su Y, Gong Z, Yao M, Liu X, et al. Gene therapy for cystic fibrosis: Challenges and prospects. *Front Pharmacol*. 2022 Oct 11;13:1015926.

## Interessenkonflikte:

A.-M. Dittrich: Seit 2015: Deutsches Bundesministerium für Bildung und Forschung: Deutsches Zentrum für Lungenforschung. Drittmittel für CF-bezogene Grundlagen- und klinische Forschung. Seit 2013: Finanzierung von klinischen Studien durch Vertex Pharmaceuticals: Zahlungen an die Einrichtung pro PatientIn/Read-out, wie im Vertrag festgelegt. 2022: Vertex Pharmaceuticals: Manuskript über Langzeiteffekte von CFTR-Modulatoren für den Thieme Verlag. Persönliche Vergütung. 2021: Advisory Board zum Einsatz von CFTR-Modulatoren bei Kleinkindern, Vertex Pharmaceuticals. Persönliche Vergütung. Seit 2015: Mitglied des deutschen CF Patientenbeirats und des wissenschaftlichen Beirats, unentgeltlich. Seit 2020: C4c, connect for children European Clinical Trial Network, Leitung der Respiratory Expert Group, unentgeltlich. Seit 2023: ECFS CTN, European CF Society Clinical Trial Network, Mitglied des Exekutivausschusses, unentgeltlich.

Katharina Schütz: Seit 2022 Finanzierung von klinischen Studien durch Vertex Pharmaceuticals: Zahlungen an die Einrichtung pro PatientIn/Read-out, wie im Vertrag festgelegt. Zahlung von Vertex und Octapharma Reisestipendien zur Teilnahme an Fortbildungen.

Dominik Funken: Seit 2023 Finanzierung von klinischen Studien durch Vertex Pharmaceuticals: Zahlungen an die Einrichtung pro PatientIn/Read-out, wie im Vertrag festgelegt.